Drug intelligence / Profile preview

A20

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal

Overview

A20 is a novel small molecule inhibitor of the EphB2 receptor. It is being investigated as a potential therapeutic agent for chronic kidney disease (CKD). In a mouse model of CKD induced by deoxycorticosterone-acetate-salt (DOCA) and angiotensin II (AII) infusion, A20 demonstrated renal protective effects, including arresting the progression of albuminuria, without impacting blood pressure. Its mechanism involves targeting EphB2 signaling, which is implicated in albuminuria, inflammation, oxidative stress, and fibrosis in kidney injury.

Targets

EPHB2 (Ephrin type-B receptor 2)

Beyond the preview

Go deeper on A20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A20.

Explore the full profile